论文部分内容阅读
在异基因骨髓移植的实验研究及临床应用中,由于供受者之间的免疫遗传学差异,移植物抗宿主病(GVHD)是一种主要致死因素。为了克服GVHD,提高骨髓移植的治疗效果,近年来许多学者对氨甲喋呤(MTX)、抗胸腺细胞球蛋白(ATG)和甲基强的松龙(MP)等免疫抑制剂的防治作用进行了大量的临床观察,但效果均不甚理想。环孢菌素A(Cyclosporin-A,CsA)作为一种新型的免疫抑制剂,已成功地用于骨髓移植的临床实践,从而为GVHD的防治开辟了一条新的途径。本文就CsA及其在异基因骨髓移植中的应用问题作一概述。
In experimental studies and clinical applications of allogeneic bone marrow transplantation, graft-versus-host disease (GVHD) is a major lethal factor due to immunodegenetic differences among donors. In order to overcome GVHD and improve the therapeutic effect of bone marrow transplantation, in recent years, many scholars have carried out a large amount of preventive and therapeutic effects on immunosuppressive agents such as methotrexate (MTX), anti-thymocyte globulin (ATG) and methylprednisolone (MP) Clinical observation, but the effect is less than ideal. As a new immunosuppressant, Cyclosporin-A (CsA) has been successfully used in the clinical practice of bone marrow transplantation, thus opening up a new way for the prevention and treatment of GVHD. This article gives an overview of CsA and its application in allogeneic bone marrow transplantation.